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Abstract:  
 
A recent article in  Gene highlighted potential function of miR-346 in human breast cancer (Yang 
et al., 2017). We request an explanation or correction of the report. In its current state, the text will 
certainly create confusion in the field and lead to incorrect assumptions. The authors made several 
critical errors. The abstract stated "we found that the expression of miR-346 was higher in breast 
cancer tissues than in their paired corresponding non-cancerous tissues" and the main text and 
legend for Fig. 1A stated "miR-346 expression was significantly higher in breast cancer tissues 
than in their paired corresponding non-cancerous tissues (Fig. 1A, Yang et al., 2017)" and "miR-
346 was upregulated in breast cancer tissues and cell lines. (A)", respectively. It was also stated 
that "SRCIN1 expression levels were significantly down-regulated in breast cancer compared to 
the adjacent normal tissues (Fig. 5B, Yang et al., 2017)". The problem with these statements is that 
they contradict the actual data presented in the paper! This misrepresentation of the effects of miR-
346 in breast cancer could prove harmful by sidetracking future research. Further, clinical trials 
may be incorrectly directed towards lowering miR-346 without a complete and fair assessment of 
the internal contradictions in the data. Inaccurately-presented data impede progress of biomedical 
research, deplete scientific resources and compromise public trust. 
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An article in recent issue of Gene highlighted potential function of a microRNA, specifically miR-
346 in human breast cancer (Yang et al., 2017). This letter is to request an explanation or correction 
of the report. In its current state, the text will certainly create confusion in the field and lead to 
incorrect assumptions. The article is therefore in need of retraction or, at the very least, an erratum 
that revises the conclusions presented in the abstract, as it appears in indices such as 
Medline/PubMed and is presumably read and accepted by several scientists who may not access 
the full text.  
 
The authors made several critical errors. Specifically, the abstract stated “we found that the 
expression of miR-346 was higher in breast cancer tissues than in their paired corresponding non-
cancerous tissues” and the main text and legend for their Fig. 1A stated “miR-346 expression was 
significantly higher in breast cancer tissues than in their paired corresponding non-cancerous 
tissues (Fig. 1A)” and “miR-346 was upregulated in breast cancer tissues and cell lines. (A)”, 
respectively. It was also stated that “SRCIN1 expression levels were significantly down-regulated 
in breast cancer compared to the adjacent normal tissues (Fig. 5B)”. 
 
The problem with these statements is that they contradict the actual data presented in the paper! 
Regarding the first statement, Fig. 1A of Yang et al. shows a mean relative expression normalized 
by U6, Ct of ~14.5 for normal tissue, while the mean value for the tumor tissue is ~13.5. The 
presented data therefore indicate that miR-346 levels in the “Tumor” tissue are lower than 
“Normal” controls. The upper error bar for “Tumor” is higher than the error bar for “Normal”, but 
that is not taken as the appropriate measure of the sample group. By contrast, the selected cell 
lines, HBL-100 (normal), MCF-7 (Tumor) and MCF-7/Doc (docetaxel-resistant) appear to follow 
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the reported trend with large and roust increases in cancer lines. These contradictory findings need 
to be explained with greater rigor.  
 
The second major claim referring to the authentic tumor tissue is that relative levels of SRCIN1 
mRNA are lower in breast cancer tissues than in non-cancerous samples. The presented data (Fig 
5B of Yang et al) actually show a higher mean value of SRCIN1 mRNA (~14 relative units) over 
normal control breast tissue (~11.5). Once again the cell line studies show that the presumably 
normal HBL-100 expresses over twice as much SRCIN-1 as the MCF-7 cancer lines (Fig. 5C of 
Yang et al).   
 
Multiple experiments were reported in the paper using “[h]uman breast cancer cell line MCF-7 
and human breast epithelial cell line HBL-100” as proxies for breast cancer and normal breast 
tissue. This is not necessarily problematic, but it is well known that cell lines are not perfect mimics 
of actual tissues or disorders. Thus, the authors wisely included data derived from actual breast 
cancer clinical samples and non-cancerous breast tissue samples. The majority of the paper 
concentrates on cell culture manipulation, and these data appear to be correctly presented. The 
problems arise when examining specific claims made by the authors regarding actual breast cancer 
tissue vs. normal breast tissue. 
 
Medical research is based on prior work, and inaccurately-presented results can only impede 
progress. Unreliable findings in biomedical research create useless “cures” and drain precious 
resources (Munafò, 2017). It is astonishing that two such glaring errors or mispresentations could 
have undetected by peer review. We do not dispute that the data is correctly described for cell 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
culture experiments, but the actual cancerous tissue results appear to directly contradict the claims 
in the article. As such, this misrepresentation of the effects of miR346 in breast cancer could prove 
harmful by sidetracking future research, at the very least. Also, clinical trials may be incorrectly 
directed towards lowering miR-346 without a complete and fair assessment of the internal 
contradictions in the data. The danger is exacerbated by emphasis of the in vivo conclusions in the 
abstract, which contradict the findings presented in the figures. 
 
In short, the tumor tissue results suggest that reduced miR-346 may associate with pathology, in 
direct contradiction to the claims made by the authors. We again strongly suggest that the paper 
and abstract be revised so text will fit the data. 
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Legends to Figures (adapted from Yang, et al., 2017) 
Fig 1. 1A (reproduced from Yang et al., 2017). “(A) The relative expression of miR-346 in breast 
cancer tissues compared with their paired corresponding non-cancerous tissues was detected by 
qRT-PCR.” 
 
Fig. 5B-C (reproduced from Yang et al., 2017). “(B) The relative expression of SRCIN1 mRNA 
in breast cancer tissues compared with their paired corresponding non-cancerous tissues was 
detected by qRT-PCR. (C) The relative expression of SRCIN1 mRNA in breast cancer cells was 
detected by qRT-PCR.” 
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Figure 1 
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Figure 5 
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